Immunocomplex capture fluorescence analysis (ICFA) which basic principle is same as Luminex crossmatch (LXM), could detect donor-specific HLA antibody (DSA). The advantages of ICFA are (i) detection of DSA and (ii) no requirement of viable cells over the flow cytometry crossmatch (FCXM). However, FCXM has been widely used because of its higher sensitivity than ICFA, in particular HLA-class II antibody detection. In this study the accuracy of DSA detection against HLA-class II was investigated by modifying the original method of ICFA. Increment of the sensitivity was found when purified peripheral blood mononuclear cells (PBMCs) were used instead of whole blood. An ICFA-PBMC in addition to FCXM-T/B was conducted for 118 patients before kidney transplantation and 13 patients with de novo DSA against HLA-class II after transplantation. Significantly positive correlation was observed between the values of ICFA-PBMC and DSA mean fluorescence intensity (MFI) targeting class II (p < 0.0001). When the cutoff level of 1.4 was determined by receiver operating characteristic curve analysis, the average DSA MFI was found to be significantly higher in the ICFA-PBMC (class II) positive group comparing to that in the negative group (12,217 vs 3885, p = 0.0027). ICFA-PBMC and optimized cutoff level could provide valid information in cases of suspected DSA.

免疫复合物捕获荧光分析（ICFA）的基本原理与Luminex crossmatch（LXM）相同，可以检测供体特异性HLA抗体（DSA）。ICFA 的优点是 (i) 检测 DSA 和 (ii) 在流式细胞术交叉匹配 (FCXM) 上不需要活细胞。然而，FCXM因其比ICFA更高的灵敏度而被广泛使用，尤其是HLA-II类抗体检测。在这项研究中，通过修改 ICFA 的原始方法，研究了 DSA 检测对 HLA-II 类的准确性。当使用纯化的外周血单核细胞 (PBMC) 代替全血时，发现灵敏度增加。一个ICFA-PBMC除了FCXM-T / B是为肾移植前118名患者和13个例进行从头移植后抗 HLA-II 类的 DSA。在 ICFA-PBMC 和 DSA 平均荧光强度 (MFI) 靶向 II 类的值之间观察到显着正相关 ( p  < 0.0001)。当通过受试者工作特征曲线分析确定 1.4 的临界值时，发现 ICFA-PBMC（II 类）阳性组的平均 DSA MFI 显着高于阴性组（12,217对3885，p  = 0.0027）。ICFA-PBMC 和优化的截止水平可以在疑似 DSA 的情况下提供有效信息。